FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138992948> ?p ?o ?g. }

• W2138992948 endingPage "1656" @default.
• W2138992948 startingPage "1647" @default.
• W2138992948 abstract "Objective:Disease-modifying therapies, such as fingolimod, interferon (IFN) and glatiramer acetate (GA), have differing effects on relapse rates in patients with multiple sclerosis (MS), but little is known about the real-world differences in relapse rates with these treatments. This retrospective study assessed relapse rates in patients with active MS initiating fingolimod, IFN or GA therapy in a real-world setting.Methods:Using administrative claims data from the US PharMetrics Plus database, we identified previously treated and untreated patients with MS who initiated fingolimod, IFN or GA treatment between 1 October 2010 and 31 March 2011 and had experienced a relapse in the previous year. A claims-based algorithm was used to identify relapses over the persistence period in patients with 540 days of post-index continuous enrolment. A logistic regression model assessed the probability of having at least one relapse and a generalized linear model estimated differences in annualized relapse rates (ARRs).Results:The study enrolled 525 patients (fingolimod, n = 128; combined IFN/GA cohort, n = 397) of the 31,041 initially identified. Similar findings for fingolimod and IFN/GA were observed for the unadjusted proportion of patients experiencing relapses (31.3% vs. 34.0%, respectively; p = 0.5653) and ARRs (0.50 vs. 0.55, respectively) while persistent to treatment. After adjusting for baseline differences, fingolimod was associated with a 52% reduction in the probability of having a relapse (odds ratio, 0.48; 95% confidence interval [CI], 0.28–0.84; p = 0.0097) and a 50% reduction in ARR (rate ratio, 0.50; 95% CI, 0.34–0.75; p = 0.0006) compared with IFN/GA.Limitations:Identification of relapses is based on the claims in the database rather than on a clinical assessment.Conclusions:In a real-world setting, fingolimod was shown to be associated with significantly lower relapse rates than IFN/GA in patients with MS who had a history of relapses." @default.
• W2138992948 created "2016-06-24" @default.
• W2138992948 creator A5002243119 @default.
• W2138992948 creator A5002442592 @default.
• W2138992948 creator A5013496211 @default.
• W2138992948 creator A5018430300 @default.
• W2138992948 creator A5024731122 @default.
• W2138992948 creator A5039001065 @default.
• W2138992948 creator A5070933892 @default.
• W2138992948 creator A5074776548 @default.
• W2138992948 creator A5077569956 @default.
• W2138992948 creator A5085553934 @default.
• W2138992948 date "2013-10-01" @default.
• W2138992948 modified "2023-10-01" @default.
• W2138992948 title "Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis" @default.
• W2138992948 cites W1581887055 @default.
• W2138992948 cites W1728920319 @default.
• W2138992948 cites W1964264880 @default.
• W2138992948 cites W1967253329 @default.
• W2138992948 cites W1974000699 @default.
• W2138992948 cites W1984705645 @default.
• W2138992948 cites W2014094373 @default.
• W2138992948 cites W2020736783 @default.
• W2138992948 cites W2025177594 @default.
• W2138992948 cites W2030592068 @default.
• W2138992948 cites W2037260636 @default.
• W2138992948 cites W2054079814 @default.
• W2138992948 cites W2061166054 @default.
• W2138992948 cites W2087589796 @default.
• W2138992948 cites W2087804398 @default.
• W2138992948 cites W2093046600 @default.
• W2138992948 cites W2104948944 @default.
• W2138992948 cites W2106412194 @default.
• W2138992948 cites W2127837073 @default.
• W2138992948 cites W2132555717 @default.
• W2138992948 cites W2135834558 @default.
• W2138992948 cites W2139367012 @default.
• W2138992948 cites W2151340435 @default.
• W2138992948 cites W2158669248 @default.
• W2138992948 cites W2704729794 @default.
• W2138992948 cites W2984556666 @default.
• W2138992948 cites W33609267 @default.
• W2138992948 cites W4210548604 @default.
• W2138992948 cites W4230052474 @default.
• W2138992948 cites W4241890711 @default.
• W2138992948 cites W4292229870 @default.
• W2138992948 doi "https://doi.org/10.1185/03007995.2013.847411" @default.
• W2138992948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24059944" @default.
• W2138992948 hasPublicationYear "2013" @default.
• W2138992948 type Work @default.
• W2138992948 sameAs 2138992948 @default.
• W2138992948 citedByCount "33" @default.
• W2138992948 countsByYear W21389929482014 @default.
• W2138992948 countsByYear W21389929482015 @default.
• W2138992948 countsByYear W21389929482016 @default.
• W2138992948 countsByYear W21389929482017 @default.
• W2138992948 countsByYear W21389929482018 @default.
• W2138992948 countsByYear W21389929482019 @default.
• W2138992948 countsByYear W21389929482020 @default.
• W2138992948 countsByYear W21389929482021 @default.
• W2138992948 countsByYear W21389929482022 @default.
• W2138992948 countsByYear W21389929482023 @default.
• W2138992948 crossrefType "journal-article" @default.
• W2138992948 hasAuthorship W2138992948A5002243119 @default.
• W2138992948 hasAuthorship W2138992948A5002442592 @default.
• W2138992948 hasAuthorship W2138992948A5013496211 @default.
• W2138992948 hasAuthorship W2138992948A5018430300 @default.
• W2138992948 hasAuthorship W2138992948A5024731122 @default.
• W2138992948 hasAuthorship W2138992948A5039001065 @default.
• W2138992948 hasAuthorship W2138992948A5070933892 @default.
• W2138992948 hasAuthorship W2138992948A5074776548 @default.
• W2138992948 hasAuthorship W2138992948A5077569956 @default.
• W2138992948 hasAuthorship W2138992948A5085553934 @default.
• W2138992948 hasConcept C126322002 @default.
• W2138992948 hasConcept C151956035 @default.
• W2138992948 hasConcept C156957248 @default.
• W2138992948 hasConcept C167135981 @default.
• W2138992948 hasConcept C203014093 @default.
• W2138992948 hasConcept C2776036978 @default.
• W2138992948 hasConcept C2778577042 @default.
• W2138992948 hasConcept C2780640218 @default.
• W2138992948 hasConcept C2781004633 @default.
• W2138992948 hasConcept C44249647 @default.
• W2138992948 hasConcept C71924100 @default.
• W2138992948 hasConcept C72563966 @default.
• W2138992948 hasConceptScore W2138992948C126322002 @default.
• W2138992948 hasConceptScore W2138992948C151956035 @default.
• W2138992948 hasConceptScore W2138992948C156957248 @default.
• W2138992948 hasConceptScore W2138992948C167135981 @default.
• W2138992948 hasConceptScore W2138992948C203014093 @default.
• W2138992948 hasConceptScore W2138992948C2776036978 @default.
• W2138992948 hasConceptScore W2138992948C2778577042 @default.
• W2138992948 hasConceptScore W2138992948C2780640218 @default.
• W2138992948 hasConceptScore W2138992948C2781004633 @default.
• W2138992948 hasConceptScore W2138992948C44249647 @default.
• W2138992948 hasConceptScore W2138992948C71924100 @default.
• W2138992948 hasConceptScore W2138992948C72563966 @default.
• W2138992948 hasIssue "12" @default.

• next